Oxaliplatin, fluorouracil and leucovorin for advanced biliary system adenocarcinomas: a prospective phase II trial

被引：0

作者：

O Nehls

B Klump

H T Arkenau

H G Hass

A Greschniok

M Gregor

R Porschen

机构：

[1] University Hospital,Department of Internal Medicine I

[2] University Hospital,Department of Pathology

[3] Clinic of Internal Medicine,undefined

[4] Central Hospital Bremen Ost,undefined

来源：

British Journal of Cancer | 2002年 / 87卷

关键词：

biliary carcinoma; chemotherapy; 5-fluorouracil; oxaliplatin;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

We studied the activity of combined oxaliplatin and fluorouracil-leucovorin in 16 consecutive patients with advanced biliary tract adenocarcinomas. The disease control rate (responses and stable disease) was 56% (95% confidence interval, 29–84%) and the median overall survival time was 9.5 months (range 0.9–26.8+). Therefore, this regimen might be active in biliary adenocarcinomas with further evaluation necessary.

引用

页码：702 / 704

页数：2

共 50 条

[31] A randomized phase III trial in patients with advanced adenocarcinoma of the stomach receiving first-line chemotherapy with fluorouracil, leucovorin and oxaliplatin (FLO) versus fluorouracil, leucovorin and cisplatin (FLP)
Al-Batran, S.
Hartmann, J. T.
Probst, S.
Hofheinz, R.
Stoehlmacher, J.
Schmalenberg, H.
Hollerbach, S.
Schuch, G.
Homann, N.
Jaeger, E.
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 934S - 934S
[32] Oxaliplatin, Leucovorin and Fluorouracil for Untreated Recurrent or Metastatic Esophageal Carcinoma - a Phase II Study
Wang, J.
Chang, J.
Yu, H.
Wang, H.
Wu, X.
Li, W.
Zhao, X.
Zheng, C.
Wang, L.
Luo, Z.
EUROPEAN JOURNAL OF CANCER, 2011, 47 : S472 - S472
[33] Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced biliary carcinoma
Sridhar Mani
David Sciortino
Brian Samuels
Rose Arrietta
Richard L. Schilsky
Everett E. Vokes
Steven Benner
Investigational New Drugs, 1999, 17 : 97 - 101
[34] Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma - A north central cancer treatment group phase II trial
Alberts, SR
Al-Khatib, H
Mahoney, MR
Burgart, L
Cera, PJ
Flynn, PJ
Flynn, PJ
Finch, TR
Levitt, R
Windschitl, HE
Knost, JA
Tschetter, LK
CANCER, 2005, 103 (01) : 111 - 118
[35] Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced biliary carcinoma
Mani, S
Sciortino, D
Samuels, B
Arrietta, R
Schilsky, RL
Vokes, EE
Benner, S
INVESTIGATIONAL NEW DRUGS, 1999, 17 (01) : 97 - 101
[36] Phase II trial of irinotecan plus oxaliplatin and 5-fluorouracil/leucovorin in patients with untreated metastatic gastric adenocarcinoma
Lee, J.
Kang, W. K.
Kwon, J. M.
Oh, S. Y.
Lee, H. R.
Kim, H. J.
Park, B. B.
Lim, H. Y.
Han, M. J.
Park, J. O.
Park, Y. S.
ANNALS OF ONCOLOGY, 2007, 18 (01) : 88 - 92
[37] Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer
Tabernero, Josep
Van Cutsem, Eric
Diaz-Rubio, Eduardo
Cervantes, Andres
Humblet, Yves
Andre, Thierry
Van Laethem, Jean-Luc
Soulie, Patrick
Casado, Esther
Verslype, Chris
Valera, Javier Sastre
Tortora, Giampaolo
Ciardiello, Fortunato
Kisker, Oliver
de Gramont, Aimery
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (33) : 5225 - 5232
[38] Phase II study of trimetrexate, fluorouracil, and leucovorin for advanced colorectal cancer
Blanke, CD
Kasimis, B
Schein, P
Capizzi, R
Kurman, M
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (03) : 915 - 920
[39] A phase II trial of 5-fluorouracil, leucovorin and mitomycin C in patients with advanced gastric cancer
Kim, Sung Rok
Yuh, Young Jin
Sohn, Byeong Seok
Yang, Sung Hyun
TUMORI, 2011, 97 (06) : 698 - 703
[40] Phase II trial of bimonthly leucovorin, 5-fluorouracil and gemcitabine for advanced pancreatic adenocarcinoma (FOLFUGEM)
Louvet, C
André, T
Hammel, P
Selle, F
Landi, B
Cattan, S
Fonck, M
Flesch, M
Colin, P
Balosso, J
Ruszniewski, P
de Gramont, A
ANNALS OF ONCOLOGY, 2001, 12 (05) : 675 - 679

← 1 2 3 4 5 →